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Abstract 
Mycolactones are macrocyclic polyketide toxins produced by the pathogen 
Mycobacterium ulcerans, the etiologic agent of the emerging human disease known as 
Bundi ulcer. A giant virulence plasmid in Mycobacterium ulcerans encoding giant 
polyketide synthases is responsible for the synthesis of the lipid toxin mycolactone. 
Mycobacterium ulcerans from different geographic origins produce varieties of 
mycolactones including mycolactone A/B, C E. Their difference is observed by thin 
layer chromagraph, mass spectrometry, cytopathic assays. The presence of different 
mycolactone correlates with plasmid variation. Australian strains lacking the hydroxyl 
group at C-12' produce a mycolactone with a mass of [M + Na]+ at rn/z 749 , called 
mycolactone C. In consistency, plasmid from Australian strains has the absence of a 
region that includes the gene encoding a P450 hydroxy lase. The product of this gene is 
predicted to hydroxylate the mycolactone side chain at C-12' to produce mycolactone 
A/8 with a mass of [M + Na]+ at rn/z 765. In order to know whether the P450 in the 
plasmid is related with the hydroxy group at C-12' in mycolactone A/B, BAC 1707 
sequence was blasted by NCBI ORF and one probable P450 open reading frame was 
found, designated P450A. The P450A sequence was cloned into expression vector 
PET30a from a BACl 707. The growth parameters controlling efficient expression of 
heme-containing P450 holoenzyme in E.coli has been tested. But most of the target 
iv 
protein was in the inclusion body. A new sequence, designated P450B, was identified by 
multi alignment which was 135 base pair shorter than the P450A. The P450B was cloned 
into pCWori vector and overexpressed. The P450B was purified from the soluble 
cytosolic fraction to electrophooretic homogeneity by affmity binding. The purified 
protein sequence was confirmed by mass spectrometry .The CO-reduced difference 
spectrum with peak at 420 nm suggests the purified protein is an inactive form of P450. 
V 
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1.1 Buruli Ulcer 
Chapter 1 
Introduction 
1.1.1 Pathogenesis and Clinical Presentation of Bundi Ulcer Disease 
Bundi ulcer, a disease caused by Mycobacterium ulcerans, has emerged as a major cause 
of human suffering since the l 980's. The infectious organism comes from the fiunily of 
Mycobacterium, which includes Mycobacterium tuberculosis and Mycobacterium /eprae. 
It is believed that Sir Albert Cook was the first one to describe the disease in his "Mengo 
Hospital Notes" in 1897 [l]. However, the connection between the ulcers and M 
u/cerans was not established until 1948. Buruli ulcer is the third most common 
mycobacterial infection in healthy people, after tuberculosis and leprosy, and the most 
poorly understood of these three diseases. 
This disease is characterized by extensive, progressive necrotizing skin lesions and the 
lack of an acute inflammatory response ( Figure 1 ) . Buruli ulcer can present in ways 
unique to different endemic regions. In Africa, the first stage of this disease is the 
formation of a firm, on-tender nodule or a plaque, and its second stage is the formation of 
a large open ulcer, or ulceration [2]. Histopathology of Buruli ulcer shows necrosis of 
S�l( ...... �stac,a): 
,.,.._ noduM. MIi .... 
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Figure 1. The progression of the Buruli ulcer lesion from the 
preulcerative stage to the ulcerative stage. (Adapted from van der Werff, 
et al.,1999.) 
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the subcutaneous fat with vascular damage, which results in sloughing and secondary 
ulceration of the overlying skin with typically undetermined edges (Figure 2). Another 
presentation of this disease is osteomyelitis. In Australia, the first sign of the disease is 
an intradermal papule or pimple. Australia and Mexico have never reported 
osteomyelitis, which is very common in Benin and West Africa Also, clinical evidence 
suggests that M ulcerans strains isolated from Asia, Mexico, and Australia may be less 
virulent than those isolated from Africa [3]. 
1.1.l Epidemiology and Transmission of Bundi Ulcer 
In the 1960's, many cases of Buruli ulcer were found in Buruli region of Uganda and 
hence the disease was named after this region. Currently Bundi ulcer is most common 
in West Africa, including all countries along the Gulf of Guinea, and an unexplained 
increase of its occurrence in this region has been reported recently. It is also found in 
marshy parts of the tropical and sub-tropical regions of Africa, Asia, Latin America and 
the Western Pacific. Sporadic cases have been reported or suspected in Angola, Australia, 
Benin, Bolivia, Burkina Faso, Cameroon, China, Congo, Cote d'Ivoire, Democratic 
Republic of Congo, Equatorial Guinea, French Guyana, Gabon, Ghana, Guinea, India, 
Indonesia, Japan, Liberia, Malaysia, Mexico, Papua New Guinea, Peru, Sierra Leone, Sri 
Lanka, Sudan, Suriname, Togo and Uganda. By now, more than 30 countries have 
reported this disease [ 4]. 
3 
Figure 2. Buruli ulcer on the right arm of a young male 
farmer. (Adapted from van der Werff, et al., 1999.) 
4 
1.1.3 Diagnosis of _Bundi Ulcer and Identification of Mycobacterium ulcerans 
In endemic areas, Bunili Ulcer is diagnosed by the clinical presentation of ulcerating 
lesions. · Its early presentation is the painless �leer without determined _ edges, 
accompanied by a necrotic slough. Lesions are located mostly on the limbs and 
occasionally on the trunk or :race. The patients usually do not have fever, or other 
inflammation. These symptoms are distinct from other bacterial infection, such as 
staphylococcal or streptococcal pyogenic infections [3]. Detection of acid-fast bacilli 
bas been used in diagnosis, but neither positive nor negative results can confirm or rule 
out the diagnosis. Culture can not be used as a routine diagnosis because it is very 
expensive and time consuming and, most importantly, it often yields fitlse-negative 
results [5]. PCR bas been used in research settings and reference laboratories for 
diagnosis. Two insertion sequences (ISs), 1S2404 and 1S2606, are highly specific for M 
ulcerans. 1S2606 is detected in only one other species, M lentijlavum. Over 40 copies 
of 1S2606 and over 50 copies of 1S2404 have been found in the genome [ 6]. The use of 
PCR probes to identify M ulcerans is highly sensitive and specific. However, it bas not 
been used as a routine diagnosis yet. 
1.1.4 Management of Bundi Ulcer Disease 
Surgery is the most effective treatment for this disease. Both small pre-ulcerative 
lesions and extensive ulcerative lesions require surgery [7]. Because it is difficult to 
5 
diagnose early infections, the surgical treatment can not be performed in very early stages, 
which will not need skin grafting. In order to prevent persistent infection and 
recurrence of this disease, the excision not only includes the necrotic tissue, but also 
extends to marginal healthy tissue [7]. 
Many antibacterial drugs such as Dapsone, streptomycin and rifampicin show very good 
results in vitro, and some combinations of them are effective in animal models, but none 
of them are effective in patients with Bundi ulcer disease [7]. The combination of 
antimycobacterial drugs and chemotherapy in treatment of patients with Bundi ulcer 
disease is not very effective. However, oral anti-microbial therapy is effective in 
patients with early nodular or very small ulcerations [7]. 
Heat treatment and hyperbaric oxygen treatment have been tried. However, considering 
the high cost and the expensive equipment, these methods have not been widely utilized 
or extensively evaluated for their effectiveness. 
1.1.5 Prevention of Bundi Ulcer Disease 
Bacillus Calmette-Guerin vaccine (BCG vaccine) has an incomplete protective effect 
against Buruli ulcers. At the present time, BCG vaccination is the only biomedical 
intervention that may help control Bundi ulcer in the highly affected areas [8]. Early 
6 
detection and prompt surgical treatment are the best interventions available until other 
means of prevention and treatment are identified. 
1.2 Mycolactone 
1.2.1 The Structure and Heterogeneity of Mycolactone 
A variety of human diseases are caused by organisms in the genus Mycobacterium. A 
major virulence determinant of M tuberculosis, M leprae and M marinum is their ability 
to survive and replicate within human macrophages. In contrast, M ulcerans is an 
extracellular infection and there is a limited inflammatory. response to the infection. 
Based on the extensive necrosis caused by M ulcerans, as early as 1965, Connor and 
· Lunn suggested a diffusible substance, such as an exotoxin, to be the primary _cause of the 
ulcers [9]. In 1974, several studies have demonstrated that the sterile filtered M 
u/cerans culture supernatant had cytopathic effects [ 10-12]. In animal tests using guinea 
pigs, the intra-dermal injection of the sterile filtrate could cause small ulcer-like lesions in 
their skin. In 1998, George, et al were able to partially purify the toxin causing this effect 
and identify the mechanism by which it functioned[12]. They found a cytotoxic activity 
associated with acetone-soluble lipids present in an organic extract from M ulcerans 
sterile filtrate. 
The cytopathic effect of M ulcerans on L 929 murine fibroblasts was characterized by 
7 
flow cytometric analysis which showed that M ulcerans . or acetone soluble lipids . 
arrested cells in the GO/G 1 stage of the cell cycle, accompanied by cytoskeletal 
rearrangement with [12]. In 1999, the toxin was completely purified and its structure 
was elucidated by mass spectral analysis and two-dimensional nuclear magnetic 
resonance spectral analysis and then confirmed by total synthesis [13-16]. 
This molecule, designated mycolactone, is a polyketide-derived macrolide from a class 
of molecules that are often biologically active. This was the first toxin isolated from a 
mycobacteria species, as well as the first complex polyketide isolated from a pathogenic 
mycobacteria [13]. It was later revealed that the compound exists as a mixture of two 
cis/trans isomers, mycolactone A/B, in equilibrium at an approximately 3:2 ratio. 
Mycolactone A/B are represented by a single peak at mass-to-charge ratio (m/z) 765.5 
upon mass spectroscopic analysis [17]. 
Analysis of liquid chromatography/mass spectrometry (LC/MS) revealed multiple 
heterogeneous congeners, which primarily differ in their number of double bonds and 
hydroxyl groups. One of the congeners gave a prominent [M+Na]+ at m/z 750 and a 
weak pseudo-molecular ion at m/z 727.5, corresponding to a mycolactone congener with 
one less oxygen atom. Another one gave a prominent ion at m/z 747.5, which, presuming 
it is also a sodium adduct, would correspond to mycolactones A and B with one less 
8 
oxygen atom and two less hydrogen atoms [18]. In 2003, the congener with peaks at 
m/z 750 (Figure 3)  was confirmed with thin layer chromatography analysis and mass 
spectrometry of acetone soluble lipids. [19] Wrth the assumption that this ion has sodiu� 
adduct, this species corresponds to mycolactone A/B, lacking an oxygen atom, which is 
consistent with the reduction in polarity observed by TLC (Figure 3). They also showed 
this congener was biologically active and designated it mycolactone C [19]. 
Mycolactone C is the predominant mycolactone in eight Australian strains analyzed and 
one of the minor mycolactone in African strains. In 2004, the structure ofmycolactone C 
was determined by total synthesis, which corresponds to C2'-deoxymycolactones A and 
B (Figure 4) [20]. The structure ofmycolacone C supports the notion that mycolactone 
C is a biosynthetic precursor of mycolactones A and B. 
Mycolactone A/B is the most potent of the M ulcerans macrolides and mycolactone C 
has been shown to be 10,000 fold less cytopathic than mycolactones A and B [19, 21], 
since Cytopathic assays (CPA) of mycolactone A/B is 0.0lng/ml, while CPA of 
mycolactone C is 800 ng/ml (CPA was defined as the minimal concentration of ASLs per 
milliliter necessary to produce 90% cell rounding in 24 h and loss of the mono layer by 48 
h)[21]. This difference in potency may partially explain the distinct · and · Jess severe 
pathology of Australian Bundi ulcer compared with Bundi ulcer from West African 
9 
MLc 
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______ ,.;A--_______ __A___ ,,- -... ,--- � ,.-_,,....-.... 
Figure 3. Silica TLC of ASLs from Mycobacterium ulcerans isolates from 
Africa, Australia, Mexico, and Asia. (Adapted from Armand Mve-Obiang, et al 
2003) Silica TLC was run in chloroform-methanol-water (90 : l 0 :  l ,  vol/vol/vol) 
and visualized by oxidative charring in a eerie molybdate- 1 0% sulfuric acid stain. 
to  
Mycolactone C 
H, Ha 
OH OH 
P450 from M ulcerans 
Mycolactone A/B 
lhe hydroxyl group added by P450 
1g + 
Ha H 
0 OH OH 
Figure 4. The proposed possible reactions of P450 from M. ulcerans of 
converting mycolactone C into mycolactone A/B. The hydroxyl group added by 
P450 was indicated by an arrow 
1 1  
strain, mycolactone profiles appear to be highly conserved within a geographic area. 
1.2.2 Genetics· of  .Biosyntbesis of Mycolactone 
In 2004, it was found that the 174-kb virulence plasmid pMUM00l in Mycobacterium 
ulcerans epidemic strain Agy99 contains three very large and homologous genes · that 
encode giant polyketide synthetase (PKS), responsible for the synthesis of the lipid toxin 
mycolactone (Figure 5). This is the first reported example of plasmid-mediated 
virulence in a mycobacterium [22, 23]. 
The 12-membered core of mycolactone is produced by two giant, modular PKSs, mlsAl 
(1.8 MDa) and mlsA2 (0.26 MDa), whereas its side chain is synthesized by mslB (1.2 
MDa), a third modular PKS highly related to mslAl . There are also some genes coding 
for potential polyketide-modifying enzymes, including a P450 monooxygenase (mup053) ,  
probably responsible for hydroxylation at carbon 12 of the side chain, and an enzyme 
resembling FabH-like type III ketosynthases (KS) (mup045) [22, 23]. 
1.2.3 Plasmid Variation Correlates with the Variety of Mycolactone . . 
As early as 2003, it was found the plasmid variation with different clinical isolates with 
geographically diverse origins [19]. In 2005 , it was also reported the plasmid variation 
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Figure S. Domain and module organization of the mycolactone PKS genes. 
(Adapted from Stinear TP , et al ,2004) Within each of the three genes (mlsAJ ,  
mlsA2, and mlsB), different domains are represented by a colored block. 
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For M ulcerans strain Chant and ITM-941331, they lack a portion of a region that 
includes the gene MUP053 (encoding a P450). The absence of MUP053 in the 
Australian M u/cerans strain Chant correlates well with the presence of mycolactone C 
and the absence ofmycolactone A/B (Figure 6) [24]. This suggests that MUP053 encodes 
a P450 whose substrate is the product of mlsB. 
1.3 Cytochrome P450 Monooxygenases 
Cytochrome P450 proteins, named for the absorption band at 450 nm of their 
carbon-monoxide-bound form, are one of the largest superfamilies of enzyme proteins. 
They are produced by a wide variety of life forms, including animals, plants, fungi and 
bacteria. Amino-acid sequences of the enzyme are extremely diverse. The identity 
between different P450s can be as low as 16% in some cases. Because of the 
differences in the peptide backbone, the enzymes have different substrate specificities. 
But all P450s contain an obligate hemecofactor. [25] This cofactor is linked to the protein 
peptide backbone via a thiolate ligand provided by a cysteine residue. The 
hemecofactor allows the enzyme to activate molecular oxygen to enable these enzymes to 
carry out diverse oxidative transformations. Their most conserved structural features 
are related to heme-binding. 
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pMUMOOl marker 
s 
JI. ulcerans strain 
(cquntry of origin) MUPO l l  mis mls.A T MUP038 MUP045 MUP053 
�pA par.A (STPK) (load) (II) (TEI!) (KSIII) (P450) 
Agy99 (Ghana) + + + + + + + + 
Kob (Ivory Coast) + + + + + + + 
16 15  (Malays ia) + + + + + + + f 
Chant (Austral ia) + + + + + + + 
IP105425 (Austral ia) + + + + + 
ITM-5 1 14 (Mexico) + + + + + 
ITM-94133 1 (Papua New + + + + + + + 
Guinea) 
ITM-941328 <Malays ia) + + + + + + + 
ITM-989 12 (People' s + + + + + + + 
Republ ic of China) 
0 1G897 (French + + + + + + + 
Guiana) 
Figure 6. PCR analysis of 10 different M. ulcerans strains for the presence 
of eight plasmid-associated genes. (Adapted from Stinear TP,et al 2005) 
abbreviation as STPK, serine/threonine protein kinase; TEii, type II thioesterase; 
KSIII, type III ketosynthase. A panel of nine M u/cerans clinical isolates with 
geographically diverse origins was collected and screened by PCR for the 
presence of eight M u/cerans plasmid markers by their corresponding primers. 
"+" represents positive result for PCR 
"-" represents negative result for PCR 
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The primary physiological role of the P450 family is that of a monooxygenase, catalyzing 
the insertion of one of the atoms of molecular oxygen into a substrate, whereas the 
second oxygen atom is reduced to water [25]. The catalytic reaction can be summarized 
as, 
where RH can be one of a large range of possible substrates. The specificity of a given 
P450 is determined by the contact residues that define the active site of the enzyme. 
These can vary widely between different P450s, however the principal component of the 
active site of all P450s is a haem moiety. The iron ion of the haem moiety is the site of 
the catalytic reaction, and is also responsible for the strong 450nm absorption peak in 
combination with CO [26]. 
1.3.1 Gene Organization and Evolutionary History 
P450 super family genes ( called CYP) are classified according to the recommendation of 
a nomenclature committee [27], on the basis of amino acid identity, phylogenetic criteria 
and gene organization. The enzymes are divided into families based on amino acid 
sequence similarity, and each fiunily can be further separated into subfamilies, which are 
designated by capital letters following the family designation (e.g., CYP3A). Individual 
enzymes are subsequently indicated by Arabic numerals ( e.g. , CYP3A4). A P450 
enzyme belongs to a specific family, when the amino acid sequence reveals more than 
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40% sequence similarity to this family. Enzymes sharing more than 55% homology form 
a subfamily to this family (Figure 7) [27]. 
1.3.2 Structural Features 
Based on the data from a number of P450 crystal structw-es, it is safe to state that the 
overall P450 . fold of is quite conservative, although · sequence identity among P450 
proteins is often · extremely low. The P450 fold is very unique since no non-P450 
structure has yet been found to share the P450 fold [28]. The general structure is 
globular, almost triangular, with the C-terminal half being helix rich and the N-terminal 
half being more beta sheet rich. The C-terminal half is more conserved. The conserved 
core consists of a four-helix (D, E, I and L) bundle, helices J and K, two sets of B sheets , 
and a coil called the 'meander' [29](figure 8). These regions includes: I> the heme 
binding ligand containing the most characteristic P450 consensus sequence which is 
usually represented as Phe-X-X-Gly-X-Arg-X-Cys-X-Gly with the absolutely conserved 
cysteine that serves as fifth ligand to the heme iron. This heme-binding region is about 
50 amino acids from the C-terminal of the protein. The helix rich half of the protein 
starts with the I-helix. 2> the consensus sequence considered as P450 signature 
Ala/Gly-Gly-X-Asp/Glu-Thr-Thr/Ser, which corresponds to the proton transfer groove on 
the distal side of the heme where the Tur residue is part of the oxygen binding site. 3> 
The K helix has an invariant Glu-X-X-Arg (EXXR) sequence which tolerates no 
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.------------ P450Mul 
-------- trlQT3ZK0IQ73ZKO MYCPA 
'-----1 splP637211CP140_MYCTU 
splP637221CP140 MYCBO 
.___-r-------------- trjQSYQP9IQ5YQJ)g_NOCFA 
.__ ____________ trjQ73YC31Q73YC3_MYCPA 
trjQ89G11,Q89G11 BRAJA L-------------------- trjQSLSZ2 Q6LSZ2,)ILPO 
i-------_;------------- trjQ9CBE7IQ9CBE7 _MYCLE .__ ____________ trjQ744J71Q74W MYCPA 
.___ __________________ trjQ7NJ901Q7NJ90_GLOVI 
tr1Q73ZK0IQ73ZK0 _MY CPA: Hypothetical protein Mycobacterium paratuberculosis 
splP6372 1 ICP140_MYCTU: Putative cytochrome P450 Mycobacterium tuberculosis 
spjP637221CP 140_MYCBO: Putative cytochrome P450 Mycobacterium bovis 
trlQ5YQP9IQ5YQP9 _NOCFA: Cytochrome P450 monooxygenase Nocardia farcinica 
tr1Q73YC3 IQ73YC3 _MYCPA: Hypothetical protein Mycobacterium paratuberculosis 
trlQ89G 1 1  IQ89G 1 1  _BRAJ A: Hypothetical protein Bradyrhizobium japonicum 
trjQ9CBE71Q9CBE7 _MY CLE: Putative cytochrome P450 Mycobacterium leprae 
tr1Q7NJ90IQ7NJ90 _ GLOVI: Putative cytochrome P450 protein Gloeobacter violaceus 
trjQ744J7IQ744J7 _MYCPA: Hypothetical protein - Mycobacterium paratuberculosis 
trjQ5LSZ2IQ5LSZ2_SILPO Cytochrome P450 protein - Silicibacter pomeroyi 
Figure 7. The phylogenetic tree of the putative cytochrome P450 M. 
ulceran with its top 10 homologous proteins. The homologous proteins of 
the putative cytochrome P450 M. ulceran were identified with the BLAST 
program from the SWISS-PROT database. Their phylogenetic tree was 
then constructed with the ClustalW program. 
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Figure 8. A ribbon representation of P450eryF crystal structure 
(Adapted from Cupp-Vickery JR et al 1995) a helices are represented by blue 
cylinders.� sheet are represented by pink arrows. The haem prosthetic group is 
embedded between the I and L helices. The floor of the substrate-binding 
pocket is formed by the haem prosthetic group and the top by the F helix. The 
sides of the pocket are formed by the I helix, the p -structure consisting of 
residues 290-296,and the fr helix. 
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substituti(?ns and is probably needed to stabilize the core structure. The E, the R and the 
C at the heme-binding site are the only completely conserved amino acids in P450s [30]. 
1.3.3 Function in Biological Systems 
The ubiquity of P450 is highlighted by recent genome sequencing projects. Although 
Escherichia coli and Salmonella typhimurium contain no P450s, Mycobacterium 
tuberculosis has. 20, Saccharomyces cerevisiae has 3, the fruit fly Drosophila 
melanogaster has 86, while humans have 57 P450s and most amazingly the plant 
Arabidopsis thaliana contains 249 different P450s [30]. These enzymes played very 
important and varied biological roles. In eukaryotes, the P450 are usually bound to the 
endoplasmic reticulum or inner mitochondrial membranes and are involved in the 
biosynthesis and catabolism of signaling molecules, steroid hormones, retinoic acid and 
in all the pathways of secondary metabolism. [31 ]. In plants, P450s are involved in the 
biosynthesis and catabolism of all types of hormones, in the oxygenation of fatty acids, 
and in all the pathways of secondary metabolism.[31]. In prokaryotes, they enable 
prokaryotes to catabolyze compounds used as carbon sources or to detoxify xenobiotics. 
Other functions described for prokaryotic P450s include fatty acid metabolism and 
biosynthesis of antibiotics. 
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1.4 Objective 
The product of M ulcerans putative P450 in the plasmid encoding the mycolactone is 
predicted to hydroxylate the mycolactone side chain of mycolactone C at Carbon-12' to 
produce mycolactone A/B. Strains lacking the hydroxyl group at C-12' produce 
mycolactone C. This is a characteristic of the Australian strains. The absence of 
putative P450 gene in Mycobacterium ulcerans strain Chant correlates well with the 
presence ofmycolactone C and the absence ofmycolactone A/B. 
The goal of my research was to clone and purify M ulcerans P450 in E. coli to study the 
structural and functional aspects of P450 enzymes in M ulcerans, A P450 in M ulcerans 
has not been expressed or analyzed. A high level of heterologous expression of M 
ulcerans in E. coli is prerequisite to prove that the substrate of the P450 is mycolactone C 
and to study the enzyme activity 
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Chapter 2 
Materials and Methods 
2.1 Subcloning of P450A Gene into PET-30a Vector 
A library of large fragment of Mulcerans 1615 was cloned into a bacterial artificial 
chromosome (BAC) library. The BAC 7017 which contains the plasmid P450 gene was 
used as the templates for the PCR amplification. Primers corresponding to regions 
flanking the p450-encoding region were used to amplify the insert via standard PCR 
protocol that engineered Ndel and Hindlll restriction sites at the 5 'and 3 'ends of the 
amplified product. The sense pruner used was 
5' -GAAGGAGATATACATATGTCCACAATCTACGGCTA-3' and the anti-sense primer 
used was 5 'CGGCCGCCATATGTCATCGGATAGCCATCGATCG-3. The P450 gene 
amplified from the BAC 7017 were double digested with Ndel and Hindlll restriction 
enzymes (New England Biolabs, Beverly, MA) at 37°C for 3 hours. The digested 
product and PET30a plasmid were gel purified using QIAquick PCR gel purification kit 
(Qiagen, Valencia, CA). Ligation was performed using approximate 3:1 insert: vector 
molar ratio and ligase used was from Promega (Madison, WI). The ligation reaction 
was done at room temperature overnight. Ligation product was transformed into 
competent TOP 10 E. coli cells following normal transformation protocol. 
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2.2 Direct Colony PCR Screening of Ligation Product 
The presence of P450 gene in PET-30a vector was first confirmed by colony screening. 
25 µl reactions were set up containing Takara ExTaq polymerase (Madison, WI) and the 
PCR reaction was performed in an Eppendorf thermal cycler (Mastercycler Gradient, 
Epperdo� Hamburg, Germany). The colony PCR primers used were T7 universal 
primer: 5 '-T AAT ACG ACT CAC TAT A_3' and reverse primer: 5 '-GAG GTT GGT 
AAT AAq GTC ATG GGT-3 '. At the same time, a patch plate was created. 6% agarose 
gel was run for the PCR products and positive colonies were grown up from the patch 
plate according to the fragment size on the gel . . Plasmid was purified and sequencing 
confirmed as mentioned in section 2.5. 
2.3 Transformation of P4S0-PET-30a and Plating 
Eleven DE3 E. coli cell lines were test for their usefulness as the expression cell lines. 
They were: BL21, BLR, HMS 174, Twner™, Novablue, Rosseta™, Rosseta-gami, 
Rosseta-gami B, Rosseta Blue, Origami ™, Origami B (Novagen, CA). 2µL of 
construct P450-PET-30a was added into 20 µL competent cell line, the tubes were kept 
on ice for 5 minutes. The tubes were placed in 4 2 'C water-bath for 30 seconds, then 
immediately on ice for 2 minutes. 250 µL SOC medium was added to each tube, 
incubated at 37°C for one hour and plated on the Kanamycin resistance plate (30 µg/ml) 
overnight. 
23 
2.3.1 Induction and Growth 
Four colonies were taken out from each specific cell line's plate into 10 ml Kanamycin 
resistance LB- medium tube. Each tube was incubated at 37, 200 Rpm until OD was 
between · 0.4--0.6. 1 ml medium was taken out from each tube, IPTG was added to the 
concentration of 1 µM, incubated at 37°C, 200 Rpm for 2 hours. 100 µL sample was 
taken from each the original uninduced and induced medium, spinned at maximum speed 
for 2 minutes. 80 µL of supernatant were removed, the left 20 µL were saved for 
SOS-PAGE. 
2.3.2 SDS-PAGE and Coomassie Brilliant Blue Detaining 
Proteins were separated by SOS-PAGE (5% acrylamide-stacking and 18% 
acrylamide-separating) and stained in Coomassie staining solution (10% acetic acid, 50% 
methanol, 0.25% Coomassie Brilliant Blue R 250) for half an hour and distained in 
distaining buffer (10% acetic acid, 50% methanol) for 30 minutes. Pictures were taken 
using UVP Biolmaging System (Upland, CA) 
2.3.3 Purification of P450 from Inclusion Bodies 
P450-PET-30a was transformed into BLR [DE3] following normal transformation 
protocol. Several colonies were inoculated into 10 ml LB (Kan 30 µg/ml) respectively, 
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and were grown at 37°C until OD600 reached 0.6. Then 1 ml culture was transferred to 
a new tube and 1 µl lM IPTG (isopropyl-b-D-thiogalactoside) was added for induction. 
An 18% polyacrylamide gel was run to determine which colony had the best expression 
and the remaining uninduced preculture ·. (9 mis) was used as inoculum for 1 L LB 
medium. IPTG was added when OD600 reached 0.6 and the cells were grown for 3 more 
hours. The cells were then spun down at 5,000 g for 10 minutes and the supernatant 
was decanted. The pellet was resuspended in 30 ml lx  Buffer A (50 mM Tris-HCL, 5 
mM MgCh, pH 7.6) and spun down at 40,000 x g for 10 minutes. Pellets were frozen at 
-80°C.  Then the next day pellets were resuspended in 30 ml lx  Buffer A +  0. 1% Triton 
X-100 and the sonicated samples were then centrifuged at 40,000 x g for 10 minutes . 
. The supernatant was decanted and 20 µl was saved for gel analysis. Then the pellet was 
resuspended with 30 ml I x  Buffer A +o.1% Triton X-100 and treated with sonication and 
centrifugation as before. This step was repeated at least 3 more times. The ·pellet was 
then rinsed with 30 ml Ix  Buffer A 3 times to remove Triton X-100. The final inclusion 
body pellet was incubated with 8 M urea + 50 mM DTT at room temperature overnight 
and then was centrifuged at 40,000 x g for 30 minutes. Supernatant was collected and 
protein was frozen at -80. 
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2.4 Generation of P450A-(his)6-PET30a Construct 
Muhi-quick site-�irected mutagenesis of P450- (His)6-PET30a was performed using 
Stratagene QuickChange muhi site-directed mutagenesis kit (Stratagene, LA, Jolla, CA). 
Single-strand primers were designed in order to change stop condon into an amino acid 
code, so the 6 histidine tag of the downstream can be expressed. The forward primer 
P450E: 5'-CGATGGCTATCCGAGGAAAGCTTGCGGCCG-3', the reverse primer 
P450F: 5'-CGGCCGCAAGCTITCCTCGGATAGCCATCG-3'. The PCR reaction was 
carried out as below: 
Step 1 Denaturation: 94 °C 4min; 
Step 2 Denaturation: 94°C lmin; 
Step 3 Annealing: ,, · 55 °C lmin; 
Step 4 Extension: 65°C 14min 
Step 5 Extension: 65 °C 7 min  
Step 6 Storage: 4°C 
The Taq polymerase pfu used was from Promega (Madison, WI). PCR product was 
transformed to XL-Blue competent cells after Dpn I treatment. Plasmids were extracted 
using Wtz.ard vacuum mini-prep kit from Promega (Madison, WI) and confirmed by 
sequencmg. 
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2.4.1 Expression and Purification of P450-(his)6-PET30a Protein 
The recombinant plasmid P450-(His)6-PET30a was used to transform BLR( A DE3) to 
kanamycin resistance. Overnight cuhures (approximately 5 ml) grown in LB medium 
containing Kanamycin ( 50 µg/ml) were used to inoculate 1 liter of the same medium. 
This cuhure was grown at 15°C until the optical density of the culture at 600 nm (0D420) 
reached 0.5. At this time, isopropyl- f3 -D-thioga1actopyranoside ( IPTG) was added to a 
fmal concentration of 1 mM, and the culture was grown for another 18 h. All 
subsequent steps were carried out at 4 °C. Cells were collected by centrifugation and 
resuspended in lysis buffer (50mM Sodium Phosphates, 300mM NaCl, PH 7.0, 0.5% 
Triton Xl 00, 3mM 2-mercaptoethanol BME). Cells were broken by passage through a 
French pressure cell at 20,000 ps( The cell extract was centrifuged at I 00,000 X g for I 
h, and the resulting supernatant was purified with Co2+-Talon Metal Affmity Resin BD 
Biosciences from Clontech (Palo Aho, CA) according to the manufacturer 's instructions. 
The Talon metal affinity resins were washed with 10 vol. of lysis buffer and then with 10 
vol of 50mM sodium phosphates, 500mM NaCl, PH 7 .0, 0.5% Triton XI 00, 3mM BME 
and finally with 10 vol. of 50mM Sodium Phosphates, 500mM NaCl, PH 7.0, 0.5% 
Triton XI00, 3mM BME, 15 mM imidazole. Elution was 50mM sodium phosphates, 
500mM NaCl, PH 7.0, 0.5% Triton XIO0, 3mM BME, 250 mM imidazole. Successful 
expression and purification were verified by SOS/PAGE. Purified recombinant protein 
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was dialyzed against lOOmM KCL, PH 7.4 , 1 5% glycerol at 4 °C by using Slide-A-Lyzer 
dialysis cassettes. ( 10,000 molecular weight cutoff, Pierce). 
2.5 Construction of P450B-(his)6 into pCWori Vector 
The probable ORF of P450-Mul. sequence was aligned with other p450 gene sequence. 
The below sequence was used to clone into pCWori vector. 
BACl 707 containing the P450 gene was used as the template for the PCR amplification. 
Primers corresponding to regions of conservative sequences were used to amplify the 
insert via standard PCR protocol that engineered Ndel in the forward site and 6 histidine 
and stop condon and Hind III restriction site in the backward site. Forward primer is 
CYP-A: 5 ':.GAAGTAGGAGGTCATATGGTGAGGCAGAGATTGAACTGG-3 ' 
Backward primer: 5' -GGTATTAAAGCTTCAATGGTGGTGATGGTGATGTCGGATA 
GCCATCGATCGTGC-3 '. The P450 gene amplified from the BAC1707 was double 
digested with Nde I and Hind/II restriction enzymes at 37 for 3 hours. The digested 
product and pCWori plasmid (nicely provided by Dr. Michael Waterman in Vanderbilt 
University) was gel pwified using QIAquick PCR gel purification kit (Qiagen, Valencia, 
CA). Ligation was performed using approximate 3 : 1  insert: vector molar ratio and the 
ligase used was from Promega (Madison, WI). The ligation reaction was done at room 
temperature overnight. Ligation product was transformed into TOP 10  competent E.coli 
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cells following standard transformation protocol. 
2.S.1 Direct Colony_ PCR Screening of Ligation Product 
The presence of P450 gene in pCWori vector w� first confirmed by colony screening. 
The PCR primer is the same. Plasmids were purified. 
2.S.2 Sequence of the P4S0B-(his),-pCWori 
The sequence forward primer is P450-Middle 1: 5' -GITGAGCCGCCGAATCAC-3 ', 
backward primer is P�50-Middle2: 5'-GTGATTCGGCGGCTCAAC-3' 
2.6 Expression and Purification of P450B-(his)6-pCWori Vector 
The method was the same as expression and purification of P450B-(His)6-PET30a 
Protein except it is the P450B- (his)6- �PCWori Vector was transformed into BLR(ADE3) 
cell lines. 
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Chapter 3 
Results 
3.1 From Gene Isolation t� Protein Purification 
3.1.1 Clonings of P450A in PET30 vector 
A M ulcerans BAC library constructed from the whole genome DNA of M ulcerans 
1615 was used as the sequence source for the P450 gene. Previous work showed that this 
gene was part of the mycolactone gene contained in the M ulcerans plasmid. BAC 1707 
contained the whole plasmid element. 
P450A sequence was identified by NCBI ORF software by scanning the full sequence of 
BAC1707.The full length of the putative P450A sequence was amplified from M 
ulcerans BAC 1707 genomic DNA by PCR, using oligonucleotides designed to introduce 
Ndel and Hindlll restriction sites. The PCR product amplified from the BAC 7017  was 
double digested with Ndel and Hind/II restriction enzymes. The DNA of pET30a vector 
was double digested with the same enzymes. Ligation was performed using 
approximately 3 : 1  insert: vector molar ratio. The ligation reaction was done at room 
temperature overnight. After transformation, colonies were screened by PCR and 
restriction digestion. The insert of one positive clone was sequenced after plasmid DNA 
isolation in order to exclude the presence of undesired mutations. The sequence was 
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100% identical to the original sequence of BAC 1707. Several screening tests were 
carried out to search for the best growth parameters for producing the most soluble 
protein of P450A. BLR cell line as phenotype as E. coli B F- dcm+ Hte ompT hsdS(rB­
mB-) gal 1 (DE3) endA Tetr produced the most soluble P450A protein under the same 
condition compared with other ten commercial cell lines tested including BL2 l ,  HMS 174, 
Tuner™, NovaBlue, Rosetta™2, Rosetta-gami, Rosetta-gami B, RosettaBlue, Origami™, 
and Origami B. (Figure 9) Thus BLR cell line was chosen as the expression cell line. 
Three different induction temperature were tested: 15 °C,  30 ·c and 3 7 °C. The results 
proved that the most soluble protein of P450A was produced at 15°C comparing at 30 °C 
and 37°C. The different induction times (3, 6, 12, 18, 24, 30 and 36 hours) and culture 
· medium (LB medium, SV medium) were also tested, but different induction times and 
culture medium didn't make much difference to the quantity of soluble protein 
production of P450A. 
The plasmid encoding P450A, designated P450A-PET30a, was specifically mutated by a 
multi-mutagenesis kit (Stratagene, LA, Jolla, CA}, producing plasmid P450A-(his)6 
-PET30a in order to facilitate purification. The expression product of plasmid 
P450A-(his)6 -PET30a contains the P450 with a six histidine tag on the C terminal for · 
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Figure 9. Soluble and insoluble protein comparison in cell line 
BL21, DLR, HMS174. 5 ml culture of different cell lines were 
induced at 1 5  °C for 1 8  hours in LB medium. The soluble and 
insoluble fraction of protein were separated by centrifugation and run on 1 2% acrylamide gel. Lane! : I : BMW marker; Lane 2 : 
Soluble fraction after induction in cell line BL2 1  ;lane 3 : Insoluble 
fraction after induction in cell line BL2 1 ; lane 4 : Soluble fraction 
after induction in cell line BLR; lane:5 : Insoluble fraction after 
induction in cell line BLR; Lane 6 : Soluble fraction after induction 
in cell line HMS I  74; lane 7 : :  Insoluble fraction after induction in 
cell line HMS I 74 
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affinity purification. The principle of purification is the 6xHis system in which six 
histidine residues are tagged to the recombinant protein. The histidine tag and protein can 
be purified using a nickel-chelating resin. The plasmid P450A-(his)6 -PET30a was 
transformed into BLR cell line and scaled up to 2 liters. After the OD600 was 0.5, IPTG 
was added until the final concentration was 1 mM. The culture was induced for 18 hours 
at 15 °C and was purified by the Talon metal affmity kit. The result was analyzed by 
SDS-PAGE. A weak band corresponding to the target protein was seen, however the 
resuhs showed that a lot of nonspecific binding occurred, (Figure 10). Resuhs from 
SOS-PAGE gel analysis of purified protein showed the presence of many proteins. In 
summary, this method did not yield highly purified protein. 
3.1 .2 Cloning, Expression and Purification of P450B in pCWori vector 
Multiple alignment analysis of the P450A sequence which was used for cloning into 
PET30a with other confirmed P450s sequence indicated that the first 135 base pairs in the 
P450A were not aligned with any other P450 sequences. [32] (Figure 11) This suggested 
that the extra 135 base pairs could be responsible for the failure to obtain soluble protein. 
The part of P450A sequence without P450A's first 135 base pair encoding amino acids 
that was the cause of insolubility, designated P450B, was aligned with other P450s using 
a "gtg" as the start codon. The P450B sequence was cloned into vector pCWori, a vector 
used previously for expressing bacterial P450's.[33]. This vector contained a TAC 
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Figure 10. Overexpression and purification of P450A. 
P450A was cloned into PET30a vector and followed by site­
specific mutation to yield a 6 histine tag on the C terminal. 
The overexpression of the fusion protein was carried out in E. 
coli at 1 5 . Expression and purity of the P450A-6His analyzed 
by 1 2% SDS-P AGE. Lane 1 :  total cell lysate from uninduced 
E. coli. Lane 2: the supernatant protein fraction from the 
induced cell lysate Lane 3: the insoluble protein (pellet) 
fraction from the induced cell lysate separated by high speed 
centrifugation. Lane 4,5,6: three times washing solution; Lane 
7,8,9 : three times elution; Lane 10 :  protein standard marker 
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P450A 
. P450B 
sp l P6372l l CPl40 MYCTU 
sp l P63722 I CP140-MYCBO 
tr l Q5YQP9 I Q5YQP9 NOCFA 
tr l Q73YC3 1 Q73YC3-MYCPA 
' tr l Q89Gll l Q89Gll-BRAJA 
tr l Q9CBE7 1 Q9CBE7-MYCLE 
tr l Q7NJ90 1 Q7NJ90-GLOVI 
tr l Q5LSZ2 I Q5LSZ2=SILPO 
P450A 
P450B 
. sp l P63721 I CP140  MYCTU 
sp l P63722 I CP140-MYCBO 
tr l Q5YQP9 1 Q5YQP9 NOCFA 
tr l Q73YC3 I Q73YC3-MYCPA 
tr l Q89Gll l Q89Gll-BRAJA 
tr l Q9CBE7 1 Q9CBE7-MYCLE 
tr l Q7NJ90 I Q7NJ90-GLOVI 
tr l Q5LSZ2 1 Q5LSZ2=SILPO 
P450A 
P450B 
sp l P6372l l CP140 MYCTU 
sp l P63722 1 CP140-MYCBO 
tr l Q5YQP9 I Q5YQP9 NOCfA 
tr l Q73YC3 I Q73YC3-MYCPA 
tr l Q89Gll l Q89Gll-BRAJA 
tr l Q9CBE7 1 Q9CBE7-MYCLE 
tr l Q7NJ90 1 Q7NJ90-GLOVI 
tr l Q5LSZ2 I Q5LSZ2=SILPO 
MSTIYGCNTM RVSTTKVRCD RHRRRRSHIK INPSHDATYV FTEGGLVRQR 
• • • • • • • • • •  • • • • • • • • • • • • • • • • • • • •  • • • • • • • • • •  • • • • • •  MRQR 
• • • • • • • • • • • • • • •  I • • • • • • •  I I • • •  I .  I • • • • • • • • • • •  I • • •  MKDK 
• • • • • • • • • • • • • • • • • • • • • • • • • • • • •  I • • • • • • • • • • • • • • • •  MKDK 
• • • • • • • • • • • • • • • • • • •  I • • • • • • • • • • • • • • • • • • • • • • • • MRLR.YW 
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • I • •  MRVRLG 
• , , • • • • • • • • • • • •  , • • • • • •  , • • • • • • • • • • • • • • • •  M VTPGSGAAIG 
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • I • • • • •  MRT CVPTRTCVY11. 
• I • • •  I • • • • • •  I • • • • •  I • • • • • • • • • •  I I • • • • • • • • • • • •  MDSVANL 
• • • •  , • • • • • • • • • • • • • • • • , • • • • • • • • • • • • • • •  MIL QPPGPGERRG 
LNWIAAHGLL RGTARLAARL GDVQSRLVAD PMVMANPAPF CDELRAIGPV 
LNWIAAHGLL RGTARLAARL GDVQSRLVAD PMVMANPAPF CDELRAIGPV 
LHWLAMHGVI RGIAAIGIRR GDLQARLIAD PAVATDPVPF YDEVRSHGAL 
LHWLAMHGVI RGIAAIGIRR GDLQARLIAD PAVATDPVPF YDEVRSHGAL 
FRWLSAQGAP RLVLRTQARR GDPFARLVGG REGIEDPYPL IEQLRGOOGP 
ARWMAMHGLP RAYFAVQARR GDPLARLLRS GTTGEDRYAL MEQIRARGPL 
VFVSCGNRFE VTMNEQAQPA GGDPLFNPLS PDFIRNPYPH YDRLRAIDPI 
FIEYLSHNR.P MGTNPPSLVE AQMLLLRLID PGTRADPFPV YRALIDYGPM 
NQDMGWTLP QTEAP • • • • • • • •  FKFNVFD PA!'BEDPYPF YDRLRRESPI 
AARQFTGRNV MSETVMQTQI GKLDLTAPP. PGFLENPFPF YDALLAHAPV 
VSSY . GTHLV VSHAIAHELL RSEDFEVVSL G . SNLPAPMR WLERRTRDDT 
VSSY . GTHLV VSHAIAHELL RSEDFEVVSL G . SNLPAPMR WLERRTRDDT 
VRNR. ANYLT VDHRIJWDLL RSDDFRVVSF G ,ENLPPPLR WLERRTRGDQ 
VRNR.ANYLT VDHRLAHDLL RSDDFRVVSF G,ENLPPPLR WLERRTRGDQ 
VRTP . LSWAA FDHELCRAIL RDNRFGVRSP QSFTMEPLK RLAAR. SPLP 
MRAP . FVWAS VDHALCRQVL RDKRFGVTSP TEMELPRPVR ALIARTDPGV 
RVTPFGQFVA SRBADVSLVM RDK • • • • •  RF GlIDFVERSKR RYSEKIMDEP 
QLPGMPLTVF SSFSDCDEAL RHP . • . •  LSA SDRLKATLAQ QAIAAGAEPR 
YRNFMiAWVF TRYSDIKSIL  RDRRFRVLDK PGWIKNXNRY LTPDQGNFDA 
LAQPDGSVLL SRHADLDRIY RDT • • • • •  TL YSSDKKAAFG • •  PKFGVGSP 
spjP6372 1 ICP140_MYCTU Putative cytochrome P450 Mycobacterium tuberculosis 
splP63 722ICP 140 _ MYCBO Putative cytochrome P450 Mycobacterium bovis 
tr1Q5YQP9IQ5YQP9 _NOCF A Cytochrome P450 Nocardia farcinica . 
tr1Q73YC3IQ73YC3_MYCPA Hypothetical protein Mycobacterium paratuberculosis 
trlQ89Gl I IQ89Gl l_BRAJA B116537 protein Bradyrhizobiumjaponicum 
trlQ9CBE7IQ9CBE7 _MYCLE Putative cytochrome p450 Mycobacterium leprae 
trlQ7NJ90IQ7NJ90 _ GLOVI Cytochrome P-450 like protein Gloeobacter violaceus 
trlQ5LSZ21Q5LSZ2_SII.,PO Cytochrome P450 family protein Silicibacter pomeroyi 
Figure 1 1. The sequence alignment of P450A, P450B and their 
homologous proteins. The homologous proteins include putative cytochrome 
P450 Mycobacterium tuberculosis; putative cytochrome P450 Mycobacterium 
bovis; cytochrome P450 Nocardiafarcinica; hypothetical protein 
Mycobacterium paratuberculosis; putative cytochrome p450 Mycobacterium 
leprae; cytochrome P-450 like protein Gloeobacter violaceus; cytochrome 
P450 family protein Silicibacter pomeroyi. These sequences were retrieved by 
NCBI database BLAST software and aligned with CLUST AL-W software. 
Only the beginning section of the multiple sequence alignment is shown.See 
reference 3 2 
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promoter, which is 15 times weaker than the T7 promoter in PET30a. The full length of 
the putative P450B sequence was amplified from M ulcerans BAC 1707 genome DNA · 
by PCR, Primers corresponding to regions of P450B sequences were used to amplify the 
insert via standard a PCR protocol that engineered Ndel in the s·site of the gene and 6 
histidines and stop condon and Hind III restriction site in the 3 · site of the gene. The p450 
gene amplified from the BAC 7017 was double digested with Ndel and HindIII _ 
restriction enzymes. The DNA of pCWori vector was double digested with the same 
enzymes. (Figures 12 , 13) Ligation was performed using approximately 3: 1 insert: vector 
molar ratio and was done at room temperature overnight. After transformation and the 
isolation of the plasmid DNA, positive clones were identified by PCR and analytical 
restriction analysis using Ndel and Hind/II (Figures 14). The insert of positive clones was 
sequenced, in order to exclude the presence of undesired mutations. One clone was 
selected for further experiments 
The soluble cytoplasmic fraction and insoluble fraction were separated by centrifugation 
and analyzed by SOS-PAGE. The over-expression of p450B-(his)6 was detected in 
soluble fraction sample as a thick protein · band corresponding to a protein at 50 kDa, 
which was consistent with the predicted molecular mass ofp450B-(his)6. This band was 
absent from the culture before induction. The culture was scaled up to 2 liters. BD 
TALON metal affinity resins were used to purify the histidine-tagged protein. The 
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BAC 1 707  l. PCR i n  th e presence of primers 
P45 0-Ndel-F and P450-Hindlll-R 
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Restriction w ith Ndel and Hind/II 
l Ligation w ith T4 ligase 
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••Cl.-1 .. .....,. ....... , ·�·, -· 
Figu re 1 2 . The scheme of the molecula r  m ethod of c lon ing  of P450B. 
The full length of the putative P45 0B sequence w as amp lified from M. 
ulcerans BAC I 707 genome DNA by  PCR, Primers corresponding to regions 
of conservative sequences were used to am plify the in sert v ia standard PCR 
protocol that eng ineered Nde/ in  the forward site and 6 h istine and stop condon 
and Hind III restriction site in .the backward site . The p45 0  gene am p l ified from 
the BAC 7 0 1 7 was dou b le d igested w ith Ndel and HindIII restriction en zymes. 
The DNA of  pCWori vector was doub le d igested w ith the same  en zym es. 
Ligation w as performed using approximate 3 :  1 insert : vector molar ratio and 
was done at room temperature overnight. 
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Figure 13. PCR result and enzyme restriction analysis of PCR product 
a> The analysis result of PCR experiment amplifying P4S0A gene. Lane 
M represents 1 .0 Kb DNA marker; lane P represents the PCR product; lane C 
represents the negative control in PCR set up in which the water was added 
instead of the template DNA b.> Enzyme restriction analysis of PCR product 
and pCWori vector. Lane M represents 1 .0 Kb DNA marker; lane] 
represents the PCR product after double digestion of Ndel and Hindi/I; lane 
V represents the pCWori DNA after double digestion of Ndel and Hind/II. 
Lane S represents the supercoiled pCWori DNA ( undigested DNA of 
pCWori) 
38 
a M E E E C 
kB 
3.0 
1.6 
1.0 
0.5 
b 
kB 
3.0 
1.6 
1.0 
0.5 
M E E E 
Figure 14. Screening of the positive E. Coli colonies. a> The PCR result of screening 
positive E.coli colonies. Lane M represented 1 .0 Kb DNA marker. Lane E represented 
the PCR result of three E.coli colonies selected randomly from the plate. b> Enzyme 
restriction analysis of the three E.coli plasmid DNA. Lane M represented 1 .0 Kb DNA 
marker; Lane E: the DNA of the plasmid after double digestion from the PCR-positive 
E.coli colony. 
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a reaction contained the detectable band with minor impwities (Figure 15) and reacted 
strongly with anti-His-tag antibodies in western blots (Figure 16). 
3.2 Protein Characterization 
3.2.1 Sequence Comparisons of the SOKda Protein 
The deduced amino acid sequence of P450B was very similar to those of many 
previously characterized P450 enzymes by protein sequence database searches. A 
CLUSTAL W alignment of P450B sequence with the well-characterized Pseudomonas 
putida P450cam (NCBI accession no. P00183) and Saccaropolyspora erythraea 
P450EryF is shown in Figure 17. Cytochrome P450eryF catalyzes the 6S-hydroxylation 
of 6-deoxyerythronolide B, the initial reaction in a multistep pathway to convert 
6-deoxyerythronolide B into the antibiotic, erythromycin. Over a position alignment, 
the three proteins shared identity, and the extent of amino acid similarity was 12%. 
A comparison with published crystallographic structures of P450cam (Protein Data Bank 
ID 5CP4) and P450 EryF revealed the conservation in P450B of individual residues and 
regions that play critical structure and functional · roles for these well-characterized 
enzymes. The below are listed some of the most common conservations: I .  Residues 
RI 12, R299, and H355 in P450cam, which serve as H-bond donors to propionate groups 
of the heme prosthetic group, are conserved in P450B (Rl 22, R320, H378, respectively). 
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Figure lS. Overexpression and purification of P450B at induction 
temperatures 30°C (part a) and 1S°C (part b). P450B was cloned 
into pCWori vector and the overexpression of the fusion protein was 
carried out in E. coli at two different temperature.Expression and 
purity of the P450B analyzed by 1 2% SOS-PAGE. Lane S: the 
. supernatant protein fraction from the induced cell lysate separated by 
high speed centrifugation. Lane P: the insoluble protein (pellet) 
fraction from the induced cell lysate separated by high speed 
centrifugation. Lane W 1 ,  W2, W3 : three times washing solution; Lane 
El ,E2,E3 : three times elution; Lane M: protein standard marker. 
4 1  
a 
U S P W1 W2 W3 E1 E2 E3 
b 
----
42 
Figure 16. Purification of P450 and 
western blot. a>Overexpression and 
purification of P450B.Lane U: total 
cell lysate from uninduced E. coli. 
Lane S: the supernatant protein 
fraction from the induced cell lysate 
Lane P :  the insoluble protein (pellet) 
fraction from the induced cell lysate 
separated by high speed 
centrifugation. Lane W 1 ,  W2, W3 : 
KDa three times washing solution ;Lane 
E l ,E2,E3 : three times elution;Lane M: 
protein standard marker b> 
98 lmmunoblot detection of P450B-
64 6xHis with anti-His-tag antibodies 
: 50 
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16 
corresponding to each lane in the 
SOS-PAGE gel. 
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Figure 17 . .  Alignment of P450B sequence with the well-characterized 
Pseudomonas putida P450cam(NCBI accession no. P00183) and 
Saccaropolyspora erythraea P450EryF. Residues marked with (*) are 
identical, while(:)indicate strong similarity and (.) weak similarity 
respectively. The boxed residues are the most conserved P450 amino acids. 
The multiple sequence alignment was performed with the CLUST AL W 
program 
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2. A high degree of sequence conservation was also found among the I and L heli�s of 
P450cam, and the· corresponding regions of P450B. �ese secondary structural features 
as the helix . I, L serve to bracket the distal and proximal faces of the heme group, 
respectively, in P450cam. 
3. Residue T253 in helix I of P450cam, which is thought to play a role in proton 
translocation during the monooxygenase reaction, is also conserved in P450B (T273). 
4. The region in P450B corresponding to the heme binding pocket, including the 
cysteinyl residue (C358 .in P450cam and C380 in P450B) that forms the proximal heme 
iron thiolate ligand, is conserved and conforms to the consensus sequence found in all 
cytochrome P450 enzymes, FXXGXXXCXG 
3.2.2 Spectroscopic Characterization 
P450 monooxygenase are good candidates for spectroscopic characterization. They 
display typical absorption spectra, which make the identification convenient. P450 shows 
the characteristic maximum at 450 nm in the reduced CO bound form which gets this 
protein the terminology of P450. The peak at 420 nm is typical for disrupted P450 
enzymes, which was caused by denaturation during purification. 
Spectra of the purified p450B-(his)6 in storage buffer were recorded from 300 to 600 nm. 
The ferric heme was then reduced by adding sodium dithionite to the protein solution, 
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and the spectrwn of the reduced enzyme was then recorded. Treatment of the sodium 
dithionite reduced sample with carbon monoxide was recorded too. Absorbance spectra 
for the ferric-oxidized, dithionite-reduced, and dithionite-reduced CO forms of 
p450B-(his)6 were shown in figure 18. P450B exhibited a Soret absorption band at 420 
nm in any form, which indicates p450B-(his)6 produced in E. coli is a heme-containing 
protein with spectral properties similar to those of catalytically inactive form P450 
enzymes-P420 form. 
3.2.3 Mass Spectrometric Analysis of the 50 Kda Protein 
The purified p450B-(his)6 recombinant protein was digested with the protease trypsin to 
· generate a mixtufe of peptides. The peptide mixture was then analyzed with liquid 
chromatogram-tandem mass spectrometry (LC-MS2) (Figure 19). Briefly, the peptides 
were separated with reverse phase liquid chromatogram, ionized with electrospray 
. ionimtion and detected with an ion trap mass spectrometer LCQ (ThermoFinnigan, San 
Jose, CA). During the mass spectrometric detection, the peptides were automatically 
selected for tandem mass spectrum measurement. The acquired tandem mass spectra 
were used to identify the measured peptides with the SEQUEST program [34]. The 
sequence database used by the SEQUEST program includes the p450B-(his)6 sequence 
and the genome sequence of Escherichia coli K 12. The identified peptides were then 
assembled to the proteins with the DTASelect program [35]. 37 peptides from the 
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Figure 18. Carbon monoxide absorption difference spectrum of 
p450B-{his)6• In part a, the black line represents the spectrum of 
oxidized p450B-(his) 6 ; the red line represents the spectrum of the 
reduced p450B-(his)6 and the green line represents the spectrum of the 
reduced p450B-(his)6 treated with carbon monoxide. Part b shows the 
absorbance difference spectrum that plots the difference in absorbance 
between the CO-bound form and the oxidized form of the p450B-(his)6 
The spectra of the purified p450B-(his)6 in storage buffer were 
recorded from 300 to 600 nm. The ferric heme was then reduced by 
adding sodium dithionite to the protein solution, and the spectrum of the 
reduced enzyme was then recorded. The spectrum of a sample that was 
reduced with sodium dithionite and then treated with carbon monoxide 
was recorded too. 
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Figure 19. Liquid chromatography-tandem mass spectrometry 
(LC-MS2) analysis. The purified P450B-(his)6 recombinant protein was digested with trypsin and the �esultant peptide mixture was · examined with LC-MS2 analysis. The base peak chromatogram is 
shown in part A. A selected tandem mass spectrum is shown in part B, 
which matches the peptide, L V ADPMVMANP APF, in the P450B­
(his )6 recombinant protein 
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p450B-(his)6 recombinant protein were identified, which covers 57% of the protein 
sequence (Figure 20). The high sequence coverage of the p450B-(his)6 protein confirms 
its presence in ·the_ sample. There are eighteen other proteins identified to be present in the 
sample (Table 1 ). They include ribosomal proteins and chaperon proteins, which are 
commonly found iD: the recombinant protein purification sample. The relative abundances 
ofp450B-(his)6 ·and the other identified proteins in the sample can be estimated with their 
spectrum count. The spectrum count of a protein is the number of tandem mass spectra 
matching to peptides from this protein, which positively correlates with the protein 
relative abundance .. In this LC-MS2 measurement, the spectrum count of p450B-(his)6 is 
more than IO-fold higher than those of the other identified proteins. This suggests a good 
purity ofp450B�(his)6 in the sample. 
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MRQ IAAHGLLRGTARLAARLGDVQSRLVADPMVMANPAPFCDE 
LRAIGPVVSSYGTHLVVSHA IAHELL EDFEVVSLGSNLPAPMRWL 
ERRTRDDTPHLLLPPSLLAVEPPNHTRY VSSVFTPKAVAGLRDH 
VEETASALLDQLTDQASAVDI IARYCSQLPVAVICDILGVPSRDRNR 
VLKFGQLAGPCIDFGLTWRQHQQVRQGLQGLHFWITEIIl.EEL NPG 
DDLMSQMIHASENGSSETHLHATEV GLVLGASFATTMDLLGNGI 
QVLIDAPELRDALSQRPQLWPNAVEEILRLEPPYQLAG DTEV 
AGTAIKRGQLVAIYLGAVNRDPSVFADP DITRAN,uu�,.......,.u SGG 
RHFCLGAALARVEGEVGL ERFPDVRAAGPGNRRDTRTLRGWSQ 
LPVQLGAARSMAIRHIIlilillH 
Figure 20. Sequence coverage of the P450B-(his)6 recombinant protein by the LC-MS2 analysis. The LC-MS2 analysis was used to identify the peptides 
from the enzymatic digestion of the purified P450B-(his \ sample . The 
identified peptides were then assembled computationally to the proteins. The 
sequence of the P450B-(his )6 recombinant protein is shown with the identified peptides highlighted in red. The more the identified peptides covers the 
protein sequences, the more confident this protein is identified. 
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Table 1. The identified proteins and their sequence coverages and spectrum 
countsc. 
i, ..... ------ -·---- -- ---· -· ... ··----- ----· -·-···-·----�------.. -. --- _,. _ ____ ___ _ - - --------
! Sequeoce : Spectnm Protein Name ,------------ --- ------ ---- -- ·:  Coverage• Cou1l 
P450B-(�)6 recombimnt protein 57% . 457 
r---- - -·--· - --- ---· -------- ·------ - ·  ...  - . --+-- - --- · -- - ----·- -- · -�- -- --- . ···-··--· -·-· -
�?OS nbosomal subtlllit_pr.o�if! !,��- - - - - -----, _ __ ____ ___ _ JQ�-- _ I O  _ ___ _ i �50S_ribosomal submit protein L28 _ ___ _ . ·-·····- �-�� _ C 7 ! 50S ribosomal subuna protein LI 7______________  1 8�-- -----·-· _2 __ !: SOS ribosomal submit_protein L2 _ _ ··· - __ ........ 12% 2 : 30S nbosomal subunl protein S 15  . 43 % 6 'chapero� Hsp70 .. i 1 7% 1 8  
- . ----- - -· -- - - --·-- . ---·--- -----�---·-- ·-- - ------- --�--- - ---- -- --- -· ----.---·--- -- . ----�--- - ---· --- -·- ·-+---� -· -- ··-·--·· ---···-1Chapero�_ Hsp60 _____ _______ ______ _ _ _ _ _ __ _ 30% i _30 __ Peptidyl prolyl cs-tram isomerase ___ _ __ __ ------ ---------·----···· , 30% ______ }�---- . -•Cyclic_ AMP_ receptor protein_ __ ____ __ _ ___ __ 29% _7 __ ......, ·Negative regulator prote� ___ _ _____ 27% 1_2_� 
[T��rip!!<?f!t�_�p�s�C>r _  oflactose catabolsm __ _ _ __ ___ ���------ ___ __ 8 __ !C_� ��d hypotretic� protein _ __ _ __ ... 23% 3 
l�ine n���� tramhydro_ge�------ - ---- __ ____ __ 11% 3 
iL-����s�6�p�sp�te-��fu�� _ __ :_ _ 12% 8 l Altronate hydroJase ! 9% · 8 ------- --------------t- - -···--------- ----(,.- �---��-·----·----� iPutative funnyltramfurase __ _____ ___ ___ ______ ________ . .  __ -- ·��------------ 5 ' ·�-oxoglutarate decarboxylase _ __ __ ______ : . ____ 8% __ ___ . -·-- ----�--- . � 
a the percentage of a protein' s  sequence covered by its identified peptides 
b the number of tandem mass spectra matching to peptides from a protein 
c David R. ·Mc Williams are acknowledged for performing the LC-MS2 
measurement and data analysis 
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Chapter 4 
Discussion 
4.1 From Gene Isolation to Protein Purification 
First expression experiments with the plasmid-encoding M ulcerans P450 protein 
resulted - in successful over expression though most of the protein obtained was insoluble 
and remained in the insoluble bodies. Several experiments were performed to determine 
the optimal host cell line and growth temperature for obtaining soluble protein. But the 
low produ� of soluble target protein prevents the further purification. Careful analysis of 
· the P450A DNA sequence indicated some reasons. There were also limitations on using 
NCBI ORF server. Because where mycobacterium has three possible start codons (atg, 
gtg, or ttg), the NCBI ORF server searches the open reading frame only by start codon 
"atg". This suggested that the sequence of P450 cloned into PET30a was not the real 
open reading frame. Multiple alignment analysis of the P450A sequence which was used 
for cloning into PET30a with other confirmed P450s sequence indicated that the first 1 35 
base pair in the P450A was not aligned with any other P450s sequence. P450B sequence 
was the part ofP450A sequence without P450A's first 135 base pair and was aligned with 
other P450s from the very beginning as start codon "gtg". Another possible reason is the 
expression vector. PET expression system is one of the most successful expression 
system in E.coli expression. It utilizes the powerful T7 phage promoter Since T7 phage 
5 1  
promoter is one of the strongest promoters, This promoter may resuh in too powerful 
protein production in form of insoluble protein. The TAC promoter used in pCWori · 
vector is 15 times weaker then the T7 promoter which may have facilitate production of 
soluble protein. 
4.2 Protein Characterization 
P450 monooxygenases are good candidates for spectroscopic characterization. 1bey 
display typical absorption spectra, which make the identification convenient. The 
inability of purified P450B to exhibit the 450-nm reduced-CO difference spectrum typical 
of P450 enzymes, but instead displaying a 420 run spectrum can be explained by the 
observation that cytochrome P450 enzymes commonly undergo, a transition to an 
inactive yet stable structural state referred to as P420, which was first described by 
Omura and Sato. It has been shown that P450-P20 conversion can be induced by 
temperature or pressure perturbations, as well as treatment with various chemicals or pH 
extrema.[36-39]. 
My inability to obtain recombinant p450B�(his)6 that exhibited reduced CO difference 
spectra with a 450nm Soret absorbance maybe caused during the purification procedures 
or improper incorporation of the heme group into the apoenzyme in E.coli. 
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